MPM Oncology Impact Management »

Sutro Biopharma shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Sutro Biopharma (STRO) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Sutro Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Sutro Biopharma held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sutro Biopharma by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $8.9M 3.0M 2.93
2024-03-31 $23M 4.1M 5.65

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Sutro Biopharma

Suvretta Capital Management
BlackRock
BlackRock
Vanguard Group
MPM Oncology Impact Management
Point72 Asset Management
Samsara BioCapital
Citadel Advisors
Kynam Capital Management
Geode Capital Management
Parkman Healthcare Partners
Acadian Asset Management
State Street Corporation
Baillie Gifford & Co
Goldman Sachs Group

View all funds holding Sutro Biopharma